Inhibition of glycogen synthase kinase by curcumin: Investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 24, Issue 3, 2009, Pages 771-778

  Bustanji, Yasser ^a   Taha, Mutasem O ^a   Almasri, Ihab M ^a   Al Ghussein, Mohamed A S ^a   Mohammad, Mohammad K ^a   Alkhatib, Hatim S ^a  

^a UNIVERSITY OF JORDAN   (Jordan)

Author keywords

Curcumin; Diabetes; Docking simulation; Glycogen synthase kinase; Inflammation

Indexed keywords

AMINO ACID; ANTIINFLAMMATORY AGENT; ANTIMALARIAL AGENT; ANTIOXIDANT; CURCUMIN; GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; DRUG ACTIVITY; DRUG BINDING; DRUG EFFECT; DRUG INHIBITION; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; EXPERIMENTAL STUDY; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL; VALIDATION STUDY; ALGORITHM; ALZHEIMER DISEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; METABOLISM; MOLECULAR DYNAMICS; PATHOLOGY;

MUS;

ALGORITHMS; ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BINDING SITES; CURCUMIN; GLYCOGEN SYNTHASE KINASE 3; MICE; MICE, INBRED BALB C; MOLECULAR DYNAMICS SIMULATION; NF-KAPPA B; PROTEIN KINASE INHIBITORS;

EID: 67649392145     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.1080/14756360802364377     Document Type: Article

References (49)

1. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. Multiple biological activities of curcumin: A short review. Life Sci 2006; 78:2081-2087.
2. Balasubramanian K. Molecular orbital basis for yellow curry spice curcumin's prevention of alzheimer's disease. J Agric Food Chem 2006;54:3512-3520.
3. Payton F, Sandusky P, Alworth WL. NMR study of the solution structure of curcumin. J Nat Prod 2007;70:143-146.
4. Fu Y, Zheng S, Lin J, Ryerse J, Chen A. Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol Pharmacol 2008;73:399-409.
5. Kohli K, Ali J, Ansari MJ, Raheman Z. Curcumin: A natural antiinflammatory agent. Indian J Pharmacol 2005;37: 141-147.
6. Sharma S, Kulkarni SK, Chopra K. Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol 2006;33: 940-945.
7. Nishiyama T, Mae T, Kishida H, Tsukagawa M, Mimaki Y, Kuroda M, Sashida Y, Takahashi K, Kawada T, Nakagawa K, Kitahara M. Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. J Agric Food Chem 2005;53: 959-963.
8. Sharma OP. Antioxidant activity of curcumin and related compounds. Biochem Pharmacol 1976;25:1811-1812.
9. Sidhu GS, Singh AK, Thaloor D, Banaudha KK, Patnaik GK, Srimal RC, Maheshwari RK. Enhancement of wound healing by curcumin in animals. Wound Repair Regen 1998;6: 167-177.
10. Negi PS, Jayaprakasha GK, Jagan Mohan Rao L, Sakariah KK. Antibacterial activity of turmeric oil: A byproduct from curcumin manufacture. J Agric Food Chem 1999;47: 4297-4300.
11. Egan ME, Pearson M, Weiner SA, Rajendran V, Rubin D, Glockner-Pagel J, Canny S, Du K, Lukacs GL, Caplan MJ. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004;304:600-602.
12. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP,Kayed R, Glabe CG, Frautschy SA, Cole GM. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005;280:5892-5901.
13. Mishra S, Karmodiya K, Surolia N, Surolia A. Synthesis and exploration of novel curcumin analogues as anti-malarial agents. Bioorg Med Chem 2008;16:2894-2902.
14. Sharma RA, Gescher AJ, Steward WP. Curcumin: The story so far. Eur J Cancer 2005;41:1955-1968.
15. Kuttan G, Kumar KB, Guruvayoorappan C, Kuttan R. Antitumor, anti-invasion, and antimetastatic effects of curcumin. Adv Exp Med Biol 2007;595:173-184.
16. Aoki H, Takada Y, Kondo S, Sawaya R, Aggarwal BB, Kondo Y. Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: Role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol 2007;72:29-39.
17. Hsu CH, Cheng AL. Clinical studies with curcumin. Adv Exp Med Biol 2007;595:471-480.
18. Dhillon N, Aggarwal BB, Newman R,Wolff R, Kunnumakkara A, Abbruzzese J, Hong D, Camacho L, Ng C, Kurzrock C. Curcumin and pancreatic cancer: Phase II clinical trial experience. J Clin Oncol ASCO Annual Meeting Proceedings 2007;25(18S):4599.
19. Cheng AL,HsuCH,Lin JK,HsuMM,HoYF, Shen TS,KoJY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or premalignant lesions. Anticancer Res 2001;21:2895-2900.
20. Balasubramanyam K, Varier RA, Altaf M, Swaminathan V, Siddappa NB, Ranga U, Kundu TK. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 2004;279:51163-51171.
21. Morimoto T, Sunagawa Y, Kawamura T, Takaya T, Wada H, Nagasawa A, Komeda M, Fujita M, Shimatsu A, Kita T, Hasegawa K. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J Clin Invest 2008;118:868-878.
22. Plummer SM, Holloway KA, Manson MM, Munks RJ, KapteinA, FarrowS,HowellsL. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 1999;18:6013-6020.
23. Lu YP, Chang RL, Huang MT, Conney AH. Inhibitory effect of curcumin on 12-O-tetradecanoylphorbol-13-acetateinduced increase in ornithine decarboxylase mRNA in mouse epidermis. Carcinogenesis 1993;14:293-297.
24. Huang TS, Lee SC, Lin JK. Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc Natl Acad Sci USA 1991;88:5292-5296.
25. Singh S, Aggarwal BB. Activation of transcription factor NFkappa B is suppressed by curcumin (diferuloylmethane). J Biol Chem 1995;270:24995-25000.
26. Demarchi F, Bertoli C, Sandy P, Schneider C. Glycogen synthase kinase-3 beta regulates NF-kappa B1/p105 stability. J Biol Chem 2003;278:39583-39590.
27. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003;101:1053-1062.
28. Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP dependent protein kinase and phosphorylase kinase. Eur J Biochem 1980;107:519-527.
29. Martinez A, Castro A, Dorronsoro I, Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev 2002;22:373-384.
30. Dorronsoro I, Castro A, Martinez A. Inhibitors of glycogen synthase kinase-3: Future therapy for unmet medical needs? Expert Opin Ther Patents 2002;12:1527-1536.
31. Alonso M, Martinez A. GSK-3 inhibitors: Discoveries and developments. Curr Med Chem 2004;11:755-763.
32. Mohammad MK, Al-Masri IM, Taha MO, Al-Ghussein MA, Alkhatib HS, Najjar S, Bustanji Y. Olanzapine inhibits glycogen synthase kinase-3beta: An investigation by docking simulation and experimental validation. Eur J Pharmacol 2008;584:185-191.
33. Taha MO, Bustanji Y, Al-Ghussein MA, Mohammad M, ZalloumH, Al-Masri IM, AtallahN. Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin. J Med Chem 2008;51:2062-2077.
34. Droucheau E, Primot A, Thomas V, Mattei D, Knockaert M, Richardson C, Sallicandro P, Alano P, Jafarshad A, Baratte B, Kunick C, Parzy D, Pearl L, Doerig C, Meijer L. Plasmodium falciparum glycogen synthase kinase-3: Molecular model, expression, intracellular localisation and selective inhibitors. Biochim Biophys Acta 2004;1697:181-196.
35. Stambolic V, Woodgett JR. Mitogen inactivation of glycogen synthase kinase-3b in intact cells via serine 9 phosphorylation. Biochem J 1994;303:701-704.
36. Bullock WH, Magnuson SR, Choi S, Gunn DE, Rudolph J. Prospects for kinase activity modulators in the treatment of diabetes and diabetic complications. Curr Top Med Chem 2002;2:915-938.
37. OMEGA VUM. OpenEye Scientific Software Inc., Santa Fe, New Mexico, Jul., 2006.
38. FRED VUM. 2006. OpenEye Scientific Software, (www.eyesopen. com), USA.
39. Bhat R, Xue Y, Berg S, Hellberg S, Ormo M, Nilsson Y, RadesaterAC, Jerning E, MarkgrenPO, BorgegardT, NylofM, Gimenez-Cassina A, Hernandez F, Lucas JJ, Diaz-Nido J, Avila J. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 2003;278:45937-45945.
40. Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput Aided Mol Des 1997; 11:425-445.
41. Cho JH, Johnson GV. Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. J Biol Chem 2003;278:187-193.
42. Martinez A, Alonso M, Castro A, Perez C, Moreno FJ. First non-ATP competitive glycogen synthase kinase 3 beta (GSK- 3beta) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem 2002;45:1292-1299.
43. Carroll NV, Longley RW, Roe JH. The determination of glycogen in liver and muscle by use of anthrone reagent. J Biol Chem 1956;220:583-593.
44. Gilson MK, Given JA, Bush BL, McCammon JA. The statistical-thermodynamic basis for computation of binding affinities: A critical review. Biophys J 1997;72:1047-1069.
45. Kontoyianni M, McClellan LM, Sokol GS. Evaluation of docking performance: Comparative data on docking algorithms. J Med Chem 2004;47:558-565.
46. Bissantz C, Folkers G, Rognan D. Protein-based virtual screening of chemical databases: Evaluation of different docking/ scoring combinations. JMed Chem 2000;43:4759-4767.
47. Vigers GP, Rizzi JP.Multiple active site corrections for docking and virtual screening. J Med Chem 2004;47:80-89.
48. Nelson DL, Cox MM. Carbohydrate biosynthesis. In: Lehninger principles of biochemistry. 3rd ed. New York: Worth Publishers; 1999. p 735-739.
49. Shojania K, Koehler BE, Elliott T. Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis. J Rheumatol 1999;26:195-196.